We are mega proud of this contract. There has never been such an agreement on the Polish biotechnology market. And in the history of Poland? It is possible that our country has never sold its technology so expensive, but we are not sure here, says Sławomir Broniarek, Member of the Management Board of OncoArendi in an interview with money.pl.
–
What was sold for such a staggering sum? Technology of chitinase inhibitors. The new drug with its use is to help in the fight against pulmonary fibrosis and asthma. By signing the contract, Galapagos NV buys the entire drug technology and the license to sell it.
–
Rafał Kamiński, also from the company’s management board, explains that the Poles managed to obtain a price for the development of molecules that block the development of pulmonary fibrosis. This disease is now killing within a few years.
–
The dissolution of the Poles may slow down or even stop this process. What is very important now, the drug can also save seriously ill people COVID-19lung fibrosis is very dangerous in the course of the disease.
–
As Marcin Szumowski explains to money.pl, President of OncoArendi, the money from the sale of technology will work on the further development of the company. There are also plans to work on a COVID-19 vaccine.
–
—
It was already famous about Marcin Szumowski’s company, but mainly thanks to the minister’s brother Łukasz Szumowski. There were allegations that OncoArendi was getting grants from the National Center for Research and Development thanks to political family connections.
–
During the previous government [Marcin Szumowski – red.] he got much more and was even more effective. I have never taken any steps in the public sphere for my brother’s company and I have spoken about it widely – explained Łukasz Szumowski in an interview with money.pl.
–
The technology company significantly gained approx. PLN 175 million. Jendak in 2018-2020, the company amounted to PLN 45 million in subsidies. Marcin Szumowski has approx. 9% of shares in the company. shares worth approx. PLN 22 million.
–
—
Michał Sołowow owns the largest block of OncoArendi shares. The richest Pole invested PLN 12 million in 2015. Recently, his block of shares is valued at about PLN 75 million.
–
